Intravenous induction followed by subcutaneous maintenance therapy with guselkumab is efficacious for adults with moderately ...

NeuroScientific Biopharmaceuticals is banking on its new, well-credentialled Perth-based chief medical officer to help the company roll out its innovative stem cell therapy.

In this video, Joseph M. Runde, DO, attending physician in gastroenterology, hepatology and nutrition at Ann & Robert H. Lurie Children’s Hospital of Chicago and assistant professor of pediatrics at ...

In this video, Joseph M. Runde, DO, attending physician in gastroenterology, hepatology and nutrition at Ann & Robert H. Lurie Children’s Hospital of Chicago and assistant professor of pediatrics at ...

Changes in sleep metrics detected with wearable technology could serve as an inflammation marker and potentially predict IBD ...

Medically reviewed by Jay N. Yepuri, MD Inflammatory bowel disease (IBD) is a group of chronic (long-term) conditions that cause inflammation in the digestive tract, which includes the mouth, ...

The drug is indicated for the treatment rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic ...

A new discovery could change how type 1 diabetes is diagnosed and managed in individuals of African descent, researchers say.

Jim Loboy interviewed Robert Lucarell, who developed Crohn’s disease in 2018; the complications were almost fatal. This ...

Researchers at New York City-based Mount Sinai Health System have identified distinct biological markers in patients with mild Crohn’s disease, potentially paving the way for more personalized and ...

Ustekinumab is more efficacious than vedolizumab or anti-TNFs as second- or third-line biologic therapy for perianal Crohn disease.